FDA Approves Ipsogen JAK2 RGQ PCR Kit to Help Evaluate Suspected Polycythemia Vera
Apr 06
2017
The U.S. Food and Drug Administration has granted marketing authorization to ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH., to detect mutations affecting the Janus Tyrosine Kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating patients for suspected Polycythemia Vera (PV).
